Pumitamig alone or with ipilimumab for first-line advanced or unresectable liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 interventional trial enrolls participants with histologically confirmed locally advanced or unresectable hepatocellular carcinoma and ECOG performance status 0–1. Participants receive pumitamig alone or pumitamig in combination with ipilimumab, with close monitoring for safety, tolerability, and tumour measurements by RECIST v1.1. The phase 1 portion follows dose-escalation principles to identify tolerable dosing, followed by phase 2 expansion to further characterize safety and preliminary activity. Key eligibility limits include no prior systemic therapy for advanced HCC and measurable disease.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Participants must have no prior systemic therapy for advanced/ unresectable HCC.
* Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria

* Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.
* Participants must not have an organ transplant or autoimmune disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

• City Of Hope
  Duarte, California, United States Recruiting
• John Theurer Cancer Center at Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting
• Laura and Isaac Perlmutter Cancer Center at NYU Langone
  Mineola, New York, United States Recruiting
• Providence Portland Medical Center
  Portland, Oregon, United States Recruiting
• Providence St. Vincent Medical Center
  Portland, Oregon, United States Recruiting
• Tennessee Oncology
  Nashville, Tennessee, United States Recruiting

+17 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TACE with sintilimab, bevacizumab, and ipilimumab N01 for advanced liver cancer

  This trial tries a combination of TACE with sintilimab and bevacizumab plus a single dose of ipilimumab N01 given at different times to see if it is safe and helps people with advanced hepatocellular carcinoma whose tumors cannot be removed.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07422753

• Comparing the ipilimumab biosimilar HLX13 with US-sourced YERVOY® as first-line treatment for unresectable liver cancer

  This study tests whether the ipilimumab biosimilar HLX13 works like US-sourced YERVOY® and is safe for adults with unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 46 sites Phase 1 Shanghai Henlius Biotech · Glendale, California and 50 other locations · NCT07176650

• Ipilimumab and nivolumab plus focused liver radiation for locally advanced liver cancer

  This trial tests whether combining nivolumab and ipilimumab with focused liver radiation (SBRT) can help adults with locally advanced hepatocellular carcinoma, with attention to including Native Hawaiian and Pacific Islander patients.

  Recruiting Phase 1 University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT07075120

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.